Rice Hall James & Associates LLC reduced its stake in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 6.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 151,656 shares of the biotechnology company’s stock after selling 10,756 shares during the period. Ascendis Pharma A/S accounts for about 1.2% of Rice Hall James & Associates LLC’s investment portfolio, making the stock its 19th biggest holding. Rice Hall James & Associates LLC owned about 0.26% of Ascendis Pharma A/S worth $20,683,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently made changes to their positions in the stock. Private Ocean LLC acquired a new position in Ascendis Pharma A/S during the 1st quarter valued at about $36,000. Quadrant Capital Group LLC grew its holdings in Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after buying an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Ascendis Pharma A/S by 37.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after buying an additional 91 shares in the last quarter. GAMMA Investing LLC increased its position in Ascendis Pharma A/S by 52.0% in the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 102 shares during the period. Finally, Barometer Capital Management Inc. bought a new stake in Ascendis Pharma A/S during the 4th quarter valued at $126,000.
Ascendis Pharma A/S Trading Down 1.8 %
Shares of Ascendis Pharma A/S stock opened at $114.76 on Wednesday. Ascendis Pharma A/S has a 1 year low of $85.29 and a 1 year high of $161.00. The company has a market cap of $6.68 billion, a P/E ratio of -11.94 and a beta of 0.63. The stock has a 50-day moving average price of $133.61 and a 200 day moving average price of $137.33.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on Ascendis Pharma A/S
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Featured Articles
- Five stocks we like better than Ascendis Pharma A/S
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Matador Resources Insiders Keep Buying Its Stock, Should You?
- What is a Low P/E Ratio and What Does it Tell Investors?
- Oracle Can Turn the Magnificent 7 Into 8: Here’s Why
- NYSE Stocks Give Investors a Variety of Quality Options
- Palantir Stock Is Up 14% on S&P 500 News: Is It Time to Buy?
Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND – Free Report).
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.